Control of Metastasis by NK Cells.

[1]  Deborah S. Barkauskas,et al.  NK cell heparanase controls tumor invasion and immune surveillance , 2024, The Journal of clinical investigation.

[2]  Lorenzo Galluzzi,et al.  Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles , 2017, Nature Reviews Drug Discovery.

[3]  Thomas R. Cox,et al.  Pre-metastatic niches: organ-specific homes for metastases , 2017, Nature Reviews Cancer.

[4]  Jeffrey A. Engelman,et al.  Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.

[5]  I. Melero,et al.  Targeting NK-cell checkpoints for cancer immunotherapy. , 2017, Current opinion in immunology.

[6]  F. Stossi,et al.  Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming , 2017, Nature.

[7]  J. Massagué,et al.  Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis , 2017, Cell.

[8]  Xiao-ming Meng,et al.  Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development , 2017, Nature Communications.

[9]  Trevor J Pugh,et al.  A distinct innate lymphoid cell population regulates tumor-associated T cells , 2017, Nature Medicine.

[10]  A. Feinberg,et al.  Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis , 2017, Nature Genetics.

[11]  Amy R. Peck,et al.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. , 2017, Cancer cell.

[12]  Camille Guillerey,et al.  Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis , 2017, Oncoimmunology.

[13]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[14]  R. Goldin,et al.  The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma , 2017, Nature Communications.

[15]  Edward Ryder,et al.  Genome-wide in vivo screen identifies novel host regulators of metastatic colonization , 2017, Nature.

[16]  U. Olsson‐Strömberg,et al.  Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia , 2016, Leukemia.

[17]  J. Condeelis,et al.  Mechanism of early dissemination and metastasis in Her2+ mammary cancer , 2016, Nature.

[18]  Rainer Spang,et al.  Early dissemination seeds metastasis in breast cancer , 2016, Nature.

[19]  P. Prorok,et al.  Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. , 2016, The New England journal of medicine.

[20]  Deborah S. Barkauskas,et al.  Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. , 2016, Cancer cell.

[21]  J. Byrd,et al.  Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia , 2016, Oncoimmunology.

[22]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[23]  Bram Boeckx,et al.  Tumor hypoxia causes DNA hypermethylation by reducing TET activity , 2016, Nature.

[24]  Xuetao Cao,et al.  Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. , 2016, Cancer cell.

[25]  Jiwang Zhang,et al.  Abstract 1491: IPH4301, an antibody targeting MICA and MICB exhibits potent cytotoxic activity and immunomodulatory properties for the treatment of cancer , 2016 .

[26]  N. Hynes,et al.  Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models , 2016, Nature Communications.

[27]  R. Hollingsworth,et al.  Targeting CD73 in the tumor microenvironment with MEDI9447 , 2016, Oncoimmunology.

[28]  Laura F. Dagley,et al.  CIS is a potent checkpoint in NK cell–mediated tumor immunity , 2016, Nature Immunology.

[29]  E. Brogi,et al.  Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling , 2016, Cell.

[30]  Romina E Araya,et al.  NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells , 2016, The Journal of Immunology.

[31]  R. Childs,et al.  Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma , 2016, Clinical Cancer Research.

[32]  M. Rantalainen,et al.  Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. , 2016, Cell reports.

[33]  S. Granjeaud,et al.  Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. , 2016, Cancer research.

[34]  E. Rankin,et al.  Hypoxic control of metastasis , 2016, Science.

[35]  Charles Swanton,et al.  Metastasis as an evolutionary process , 2016, Science.

[36]  R. Weinberg,et al.  Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. , 2016, Cancer discovery.

[37]  Elisa de Stanchina,et al.  Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT , 2016, Cell.

[38]  L. Zitvogel,et al.  Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy , 2016, Oncoimmunology.

[39]  I. Nookaew,et al.  Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. , 2016, Cell metabolism.

[40]  L. Zitvogel,et al.  Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy , 2016, Oncoimmunology.

[41]  David K. Finlay,et al.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway , 2016, Science Signaling.

[42]  Z. Bago-Horvath,et al.  STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. , 2016, Cancer discovery.

[43]  B. Edil,et al.  Br Ief Definitive Repor T Identification of Cd112r as a Novel Checkpoint for Human T Cells , 2022 .

[44]  L. Zitvogel,et al.  Trial Watch—Immunostimulation with cytokines in cancer therapy , 2016, Oncoimmunology.

[45]  L. Lanier,et al.  Natural killer cell memory in infection, inflammation and cancer , 2016, Nature Reviews Immunology.

[46]  J. Polansky,et al.  High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner , 2016, Scientific Reports.

[47]  J. Massagué,et al.  Metastatic colonization by circulating tumour cells , 2016, Nature.

[48]  John J Miles,et al.  Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. , 2016, Cancer discovery.

[49]  C. Isacke,et al.  Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness , 2016, Nature Communications.

[50]  G. Berchem,et al.  Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer , 2015, Oncoimmunology.

[51]  I. Malanchi,et al.  Neutrophils support lung colonization of metastasis-initiating breast cancer cells , 2015, Nature.

[52]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[53]  Stephen T. C. Wong,et al.  EMT is not required for lung metastasis but contributes to chemoresistance , 2015, Nature.

[54]  D. Metzger,et al.  Patrolling monocytes control tumor metastasis to the lung , 2015, Science.

[55]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[56]  Pieter Wesseling,et al.  RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics , 2015, Cancer cell.

[57]  B. Lambrecht,et al.  Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection , 2015, The Journal of experimental medicine.

[58]  Jun Yao,et al.  Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth , 2015, Nature.

[59]  S. Levy,et al.  Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. , 2015, Cancer research.

[60]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[61]  T. Sayers,et al.  NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype , 2015, The Journal of Immunology.

[62]  N. Beauchemin,et al.  The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity. , 2015, Immunity.

[63]  M. Caligiuri,et al.  CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells , 2015, Scientific Reports.

[64]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[65]  A. Santoni,et al.  Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells , 2015, The Journal of Immunology.

[66]  T. Brümmendorf,et al.  JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. , 2015, Cancer research.

[67]  M. Caligiuri,et al.  A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma , 2015, Clinical Cancer Research.

[68]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[69]  L. Zitvogel,et al.  Trial Watch: Adoptive cell transfer for oncological indications , 2015, Oncoimmunology.

[70]  L. Zitvogel,et al.  Natural killer cell mediated immunosurveillance of pediatric neuroblastoma , 2015, Oncoimmunology.

[71]  B. Fingleton,et al.  Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. , 2015, Cancer research.

[72]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[73]  F. Souza-Fonseca-Guimaraes,et al.  DNAM-1 expression marks an alternative program of NK cell maturation. , 2015, Cell reports.

[74]  L. Zitvogel,et al.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications , 2015, Oncoimmunology.

[75]  Benjamin G. Gowen,et al.  A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection , 2015, Science.

[76]  A. Möller,et al.  Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis , 2015, Oncoimmunology.

[77]  Seamus J. Martin,et al.  Autophagy in malignant transformation and cancer progression , 2015, The EMBO journal.

[78]  Cyrus M. Ghajar.  Metastasis prevention by targeting the dormant niche , 2015, Nature Reviews Cancer.

[79]  O. Mandelboim,et al.  Characterization of tumor infiltrating Natural Killer cell subset , 2015, Oncotarget.

[80]  Nicholas K. Brown,et al.  CD160 is essential for NK-mediated IFN-γ production , 2015, The Journal of experimental medicine.

[81]  Akio Ohta,et al.  Immunological mechanisms of the antitumor effects of supplemental oxygenation , 2015, Science Translational Medicine.

[82]  Jennifer D. Wu,et al.  NKG2D Ligands in Tumor Immunity: Two Sides of a Coin , 2015, Front. Immunol..

[83]  M. Caligiuri,et al.  PTEN Is a Negative Regulator of NK Cell Cytolytic Function , 2015, The Journal of Immunology.

[84]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[85]  Bijal A. Parikh,et al.  PTEN regulates natural killer cell trafficking in vivo , 2014, Proceedings of the National Academy of Sciences.

[86]  N. Rouas-Freiss,et al.  HLA-G: An Immune Checkpoint Molecule. , 2015, Advances in immunology.

[87]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[89]  L. Zitvogel,et al.  Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. , 2014, Cancer research.

[90]  J. Linden,et al.  Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. , 2014, Cancer research.

[91]  G. Matarese,et al.  Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumor infiltrated lymph nodes of melanoma patients , 2014, Nature Communications.

[92]  H. Fehling,et al.  Conditional ablation of NKp46+ cells using a novel Ncr1greenCre mouse strain: NK cells are essential for protection against pulmonary B16 metastases , 2014, European journal of immunology.

[93]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[94]  V. Poli,et al.  Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. , 2014, Blood.

[95]  A. Strasser,et al.  Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells , 2014, Nature Communications.

[96]  M. Smyth,et al.  Targeting cancer-derived adenosine: new therapeutic approaches. , 2014, Cancer discovery.

[97]  S. Lye,et al.  Leukocyte driven-decidual angiogenesis in early pregnancy , 2014, Cellular and Molecular Immunology.

[98]  M. Smyth,et al.  Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. , 2014, Cancer research.

[99]  W. Gorczyca,et al.  Complement C 5 a receptor facilitates cancer metastasis by altering T cell responses in the metastatic niche , 2014 .

[100]  P. Altevogt,et al.  Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. , 2014, Cancer research.

[101]  R. Braylan,et al.  A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma , 2014, Haematologica.

[102]  F. Souza-Fonseca-Guimaraes,et al.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions , 2014, Nature Immunology.

[103]  A. Ullrich,et al.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells , 2014, Nature.

[104]  C. Rice,et al.  Interferon-stimulated genes: a complex web of host defenses. , 2014, Annual review of immunology.

[105]  M. Speicher,et al.  Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients , 2014, Science Translational Medicine.

[106]  A. Agha,et al.  KLRG1+ NK Cells Protect T-bet–Deficient Mice from Pulmonary Metastatic Colorectal Carcinoma , 2014, The Journal of Immunology.

[107]  M. Jakóbisiak,et al.  Interleukin 12: still a promising candidate for tumor immunotherapy? , 2014, Cancer Immunology, Immunotherapy.

[108]  L. Galluzzi,et al.  Novel insights into the mechanism of action of lenalidomide , 2014, Oncoimmunology.

[109]  H. Kohrt,et al.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. , 2013, Blood.

[110]  L. Moretta,et al.  Dendritic cell editing by natural killer cells. , 2014, Critical reviews in oncogenesis.

[111]  L. Zitvogel,et al.  Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. , 2014, Cancer research.

[112]  L. Zitvogel,et al.  Trial Watch , 2013, Oncoimmunology.

[113]  J. Zimmer,et al.  Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia , 2013, Proceedings of the National Academy of Sciences.

[114]  O. Janssen,et al.  Shedding of endogenous MHC class I‐related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17 , 2013, International journal of cancer.

[115]  C. Klein.  Selection and adaptation during metastatic cancer progression , 2013, Nature.

[116]  M. Smyth,et al.  Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors , 2013, Proceedings of the National Academy of Sciences.

[117]  W. Pickl,et al.  CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance , 2013, Cell reports.

[118]  A. Madrigal,et al.  Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy , 2013, Cellular and Molecular Immunology.

[119]  A. G. de Herreros,et al.  Epithelial–Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor , 2013, The Journal of Immunology.

[120]  T. Graeber,et al.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. , 2013, The Journal of clinical investigation.

[121]  Rosanna La Rocca,et al.  Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules , 2013, The Journal of Immunology.

[122]  D. Noonan,et al.  The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. , 2013, Neoplasia.

[123]  A. McKenzie,et al.  Innate lymphoid cells — how did we miss them? , 2013, Nature Reviews Immunology.

[124]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[125]  H. Brinkhaus,et al.  JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. , 2012, Cancer cell.

[126]  M. Caligiuri,et al.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. , 2012, Blood.

[127]  J. Tschopp,et al.  NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. , 2012, Cancer research.

[128]  Lisa M. Schwartz,et al.  Cancer screening campaigns--getting past uninformative persuasion. , 2012, The New England journal of medicine.

[129]  Ben S. Wittner,et al.  Corrigendum: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis , 2012, Nature.

[130]  D. Bowtell,et al.  Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. , 2012, Cancer research.

[131]  M. Nakamoto,et al.  Diagnostic and prognostic impact of serum‐soluble UL16‐binding protein 2 in lung cancer patients , 2012, Cancer science.

[132]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[133]  L. Moretta,et al.  Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response , 2012, PloS one.

[134]  Sridhar Ramaswamy,et al.  RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis , 2012, Nature.

[135]  Mark J. Smyth,et al.  Cancer immunoediting by the innate immune system in the absence of adaptive immunity , 2012, The Journal of experimental medicine.

[136]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[137]  N. Stanietsky,et al.  Recognition and Prevention of Tumor Metastasis by the NK Receptor NKp46/NCR1 , 2012, The Journal of Immunology.

[138]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[139]  H. Rammensee,et al.  Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. , 2012, Cancer research.

[140]  R. Welsh,et al.  Natural killer cells act as rheostats modulating antiviral T cells , 2011, Nature.

[141]  M. Caligiuri,et al.  IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. , 2011, Blood.

[142]  P. Validire,et al.  Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. , 2011, Cancer research.

[143]  Jan Tavernier,et al.  Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors , 2011, Nature Medicine.

[144]  H. Karasuyama,et al.  NK Cell-Depleting Anti-Asialo GM1 Antibody Exhibits a Lethal Off-Target Effect on Basophils In Vivo , 2011, The Journal of Immunology.

[145]  E. Casanova,et al.  A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. , 2011, Blood.

[146]  J. Steffensen,et al.  Hypoxia-induced metastasis model in embryonic zebrafish , 2010, Nature Protocols.

[147]  C. Bokemeyer,et al.  Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. , 2010, Cancer treatment reviews.

[148]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[149]  Takashi Murakami,et al.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. , 2010, Gastroenterology.

[150]  N. Ragni,et al.  Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression , 2010, Proceedings of the National Academy of Sciences.

[151]  M. Smyth,et al.  Innate immunity defines the capacity of antiviral T cells to limit persistent infection , 2010, The Journal of experimental medicine.

[152]  R. Welsh,et al.  Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. , 2010, The Journal of clinical investigation.

[153]  M. Sliwkowski,et al.  Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. , 2010, Cancer research.

[154]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[155]  Qian Wang,et al.  Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. , 2010, Blood.

[156]  Gang Liu,et al.  Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and Metalloproteinases , 2010, The Journal of Immunology.

[157]  M. Colonna,et al.  DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases , 2009, The Journal of Immunology.

[158]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[159]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[160]  H. Salih,et al.  Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. , 2009, Cancer research.

[161]  A. Mes-Masson,et al.  Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. , 2009, Journal of immunological methods.

[162]  D. Schadendorf,et al.  Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B , 2009, Clinical Cancer Research.

[163]  H. Pircher,et al.  Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition. , 2009, Immunity.

[164]  H. Welch.  Overdiagnosis and mammography screening , 2009, BMJ : British Medical Journal.

[165]  Larry Norton,et al.  Latent bone metastasis in breast cancer tied to Src-dependent survival signals. , 2009, Cancer cell.

[166]  S Gonzalez,et al.  HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer , 2009, Oncogene.

[167]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[168]  D. Schadendorf,et al.  NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. , 2009, The Journal of clinical investigation.

[169]  J. Blay,et al.  Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. , 2009, Cancer research.

[170]  P. L. Poliani,et al.  NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties1 , 2009, The Journal of Immunology.

[171]  Xuetao Cao,et al.  Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.

[172]  T. Yasui,et al.  Accelerated tumor growth in mice deficient in DNAM-1 receptor , 2008, The Journal of experimental medicine.

[173]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[174]  L. Glimcher,et al.  T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease1 , 2008, The Journal of Immunology.

[175]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[176]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[177]  M. Czuczman,et al.  Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.

[178]  M. Smyth.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[179]  Tong Zhang,et al.  NK Cells Negatively Regulate Antigen Presentation and Tumor-Specific CTLs in a Syngeneic Lymphoma Model1 , 2007, The Journal of Immunology.

[180]  Dale L. Greiner,et al.  Humanized mice in translational biomedical research , 2007, Nature Reviews Immunology.

[181]  L. Moretta,et al.  The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. , 2006, Blood.

[182]  J. Hanna,et al.  Decidual NK cells regulate key developmental processes at the human fetal-maternal interface , 2006, Nature Medicine.

[183]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[185]  Michael Bitzer,et al.  Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. , 2005, Cancer research.

[186]  R. Schreiber,et al.  Interferon-γ and cancer immunoediting , 2005 .

[187]  R. Schreiber,et al.  Interferon-gamma and cancer immunoediting. , 2005, Immunologic research.

[188]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[189]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[190]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[191]  A. Giaccia,et al.  Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. , 2002, Cancer cell.

[192]  M. G. Jiménez,et al.  Membrane-Type Matrix Metalloproteinases , 2002 .

[193]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[194]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[195]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[196]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[197]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[198]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[199]  M. Smyth,et al.  Perforin is a major contributor to NK cell control of tumor metastasis. , 1999, Journal of immunology.

[200]  P. Ricciardi-Castagnoli,et al.  Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.

[201]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[202]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[203]  P. Mcculloch,et al.  Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. , 1989, British Journal of Cancer.

[204]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[205]  A. Ketcham,et al.  Reduced Incidence of Spontaneous Metastases with Long‐Term Coumadin* Therapy , 1968, Annals of surgery.